William Arcese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/333661/publications.pdf

Version: 2024-02-01

208 papers 14,241 citations

47409 49 h-index 23173 116 g-index

209 all docs 209 docs citations

209 times ranked 8592 citing authors

#	Article	IF	CITATIONS
1	ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol. Blood Advances, 2022, 6, 2510-2516.	2.5	3
2	Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients. Biomedicines, 2022, 10, 443.	1.4	4
3	Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2021, 56, 1391-1401.	1.3	24
4	Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1593-1602.	1.3	8
5	Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation. Cancers, 2021, 13, 1083.	1.7	3
6	Legionellosis after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 255-2566.	1.3	1
7	Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation, 2021, 56, 2367-2381.	1.3	1
8	Impact of early candidemia on the long-term outcome of allogeneic hematopoietic stem cell transplant in non-leukemic patients: an outcome analysis on behalf of IDWP–EBMT. Bone Marrow Transplantation, 2021, 56, 1563-1572.	1.3	1
9	CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia. Leukemia and Lymphoma, 2021, , 1-5.	0.6	1
10	Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT. Leukemia, 2020, 34, 87-99.	3.3	25
11	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 1113-1118.	2.0	3
12	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. American Journal of Hematology, 2019, 94, 1091-1097.	2.0	25
13	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. Journal of Hematology and Oncology, 2019, 12, 68.	6.9	22
14	Cerebellar Neurocysticercosis as Long-Term Complication of Allogeneic Haematopoietic Stem Cell Transplantation from Haploidentical Donor. Case Reports in Infectious Diseases, 2019, 2019, 1-4.	0.2	0
15	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood, 2019, 134, 935-945.	0.6	148
16	Polyomaviruses shedding in stool of patients with hematological disorders: detection analysis and study of the non-coding control region's genetic variability. Medical Microbiology and Immunology, 2019, 208, 845-854.	2.6	5
17	Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?. International Journal of Molecular Sciences, 2019, 20, 1373.	1.8	15
18	Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo. Biology of Blood and Marrow Transplantation, 2019, 25, 1387-1394.	2.0	2

#	Article	IF	Citations
19	Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. Supportive Care in Cancer, 2019, 27, 793-803.	1.0	8
20	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. Leukemia, 2019, 33, 1527-1530.	3. 3	16
21	Prof. Franco Mandelli Leukaemia Visionary. May 12, 1931– July 15, 2018. Leukemia, 2019, 33, 285-286.	3. 3	0
22	Endoscopic Intravesical Fibrin Glue Application in the Treatment of Refractory Hemorrhagic Radiation Cystitis: A Single Cohort Pilot Study. Journal of Endourology, 2019, 33, 93-98.	1.1	10
23	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. Expert Review of Hematology, 2018, 11, 307-313.	1.0	21
24	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. Seminars in Hematology, 2018, 55, 209-214.	1.8	39
25	Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. American lournal of Hematology, 2018, 93, 859-866.	2.0	28
26	Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 161-162.	0.2	2
27	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. Journal of Hematology and Oncology, 2018, 11, 110.	6.9	41
28	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. American Journal of Hematology, 2018, 93, 1211-1219.	2.0	20
29	Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission—Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT), Cancer, 2017, 123, 824-831.	2.0	32
30	The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy. Transfusion, 2017, 57, 1734-1743.	0.8	10
31	Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transplantation, 2017, 52, 473-475.	1.3	21
32	Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. British Journal of Haematology, 2017, 179, 790-801.	1.2	9
33	An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia. Clinical Cancer Research, 2017, 23, 6478-6486.	3.2	28
34	Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper. Clinical Microbiology and Infection, 2017, 23, 935-940.	2.8	69
35	Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study. Bone Marrow Transplantation, 2017, 52, 154-156.	1.3	27
36	Thiotepaâ€based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemiaâ€"A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2017, 92, 18-22.	2.0	11

#	Article	IF	CITATIONS
37	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. Bone Marrow Transplantation, 2017, 52, 163-166.	1.3	24
38	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clinical Infectious Diseases, 2017, 65, 1884-1896.	2.9	103
39	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Advances, 2017, 1, 669-680.	2.5	43
40	IDENTIFICATION OF ORAL RISK FACTORS FOR CHRONIC GRAFT VERSUS HOST DISEASE IN HAEMATOLOGICAL PATIENTS WHO UNDERWENT ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION. ORAL and Implantology, 2017, 10, 390.	0.3	3
41	THERAPEUTIC EFFICIENCY OF PLATELET GEL FOR THE TREATMENT OF ORAL ULCERS RELATED TO CHRONIC GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION. ORAL and Implantology, 2017, 10, 398.	0.3	12
42	Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation. Blood, 2017, 130, 850-850.	0.6	0
43	MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016052.	0.5	18
44	Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. Journal of Hematology and Oncology, 2016, 9, 79.	6.9	42
45	Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clinical Microbiology and Infection, 2016, 22, 946.e1-946.e8.	2.8	25
46	Patientâ€reported outcomes and quality of life assessment: New targets for new targeted therapy?. Cancer, 2016, 122, 1461-1462.	2.0	2
47	Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. Journal of Infection, 2016, 72, 265-268.	1.7	17
48	Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. Annals of Hematology, 2016, 95, 967-972.	0.8	6
49	Rehabilitation need and referrals in hematopoietic stem cell transplantation: the experience of Quality of Life Working Party of the Rome Transplant Network. Bone Marrow Transplantation, 2016, 51, 638-639.	1.3	0
50	Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update. Bone Marrow Transplantation, 2015, 50, S24-S30.	1.3	35
51	A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia, 2015, 29, 1069-1075.	3.3	57
52	Platelet-rich plasma as treatment for persistent ocular epithelial defects. Transfusion and Apheresis Science, 2015, 52, 300-304.	0.5	38
53	Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need. Supportive Care in Cancer, 2015, 23, 2211-2211.	1.0	6
54	Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia, 2015, 29, 1891-1900.	3.3	199

#	Article	IF	Citations
55	Minimal residual disease as biomarker for optimal biologic dosing of ⟨scp⟩ARA⟨/scp⟩â€⟨scp⟩C⟨/scp⟩ in patients with acute myeloid leukemia. American Journal of Hematology, 2015, 90, 125-131.	2.0	12
56	HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 399-399.	0.6	2
57	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 3211-3211.	0.6	3
58	Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4316-4316.	0.6	0
59	Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended Analysis. Journal of Clinical Oncology, 2014, 32, 3347-3348.	0.8	85
60	Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia, 2014, 28, 779-786.	3.3	95
61	Development of cellulitis caused by Aeromonas hydrophila in allogeneic hematopoietic transplantation: a case report. Bone Marrow Transplantation, 2014, 49, 595-596.	1.3	2
62	High incidence of postâ€transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomibâ€based regimens: a survey from the Rome Transplant Network. Transplant Infectious Disease, 2014, 16, 158-164.	0.7	38
63	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. Haematologica, 2014, 99, 1509-1515.	1.7	48
64	Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Haematologica, 2014, 99, 1380-1386.	1.7	31
65	Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis. Bone Marrow Transplantation, 2014, 49, 24-29.	1.3	31
66	Fibrin Glue Therapy for Severe Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1612-1617.	2.0	35
67	Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2014, 49, 887-894.	1.3	23
68	Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplantation, 2014, 49, 1170-1175.	1.3	33
69	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biology of Blood and Marrow Transplantation, 2014, 20, 872-880.	2.0	141
70	Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood, 2014, 123, 133-140.	0.6	239
71	3-Tesla MR spectroscopy in patients subjected to bone marrow transplantation: clinical correlations. Radiologia Medica, 2013, 118, 101-111.	4.7	2
72	Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score. Supportive Care in Cancer, 2013, 21, 5-6.	1.0	6

#	Article	IF	CITATIONS
73	Impact of Graft-versus-Host Disease Prophylaxis on Outcomes after Myeloablative Single-Unit Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1387-1392.	2.0	24
74	Quality-of-Life Monitoring During Hematopoietic Stem Cell Transplantation: Observations and a Suggestion From the Rome Transplant Network Quality of Life Working Party. Journal of Pain and Symptom Management, 2013, 45, e2-e3.	0.6	6
75	Monitoring of KI and WU polyomaviruses in hematopoietic stem cell transplant patients. Journal of Medical Virology, 2013, 85, 1122-1124.	2.5	8
76	Bowel ultrasonography as an aid for diagnosis of intestinal acute graft-versus-host-disease after allogeneic haematopoietic stem cell transplantation. Digestive and Liver Disease, 2013, 45, 899-904.	0.4	5
77	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. Leukemia, 2013, 27, 2086-2091.	3.3	37
78	Haploidentical, unmanipulated, G-CSF–primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood, 2013, 121, 849-857.	0.6	209
79	Allogeneic Hematopoietic Cell Transplantation For Patients With Mycosis Fungoides and Sezary Syndrome: The Experience Of The EBMT Lymphoma Working Party With An Extended Five-Year Follow Up. Blood, 2013, 122, 2094-2094.	0.6	2
80	T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT. Blood, 2013, 122, 3359-3359.	0.6	11
81	Unmanipulated Graft Haploindentical Allogeneic Stem Cell Transplantation (Haplo-SCT) In Acute Leukemia: A Long-Term Follow-Up Survey On Behalf Of The Acute Leukemia Working Party (ALWP) Of The European Group For Blood and Marrow Transplantation (EBMT). Blood, 2013, 122, 2105-2105.	0.6	0
82	Haploidentical, Unmanipulated, G-CSF-Primed Bone Marrow Transplantation For Patients With High-Risk Acute Myeloid Leukemia. Blood, 2013, 122, 3356-3356.	0.6	0
83	Granulocyte-mobilized bone marrow. Current Opinion in Hematology, 2012, 19, 448-453.	1.2	8
84	Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era. Haematologica, 2012, 97, 1731-1735.	1.7	22
85	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia, 2012, 26, 1779-1785.	3.3	14
86	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood, 2012, 119, 332-341.	0.6	246
87	Concurrent search for unrelated cord and volunteer donor in high-risk acute lymphoblastic leukemia. Annals of Hematology, 2012, 91, 941-948.	0.8	4
88	Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant. Supportive Care in Cancer, 2012, 20, 891-892.	1.0	10
89	The potential role of preâ€transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant Network. American Journal of Hematology, 2012, 87. 213-217.	2.0	14
90	Hospital Cluster of HBV Infection: Molecular Evidence of Patient-to-Patient Transmission through Lancing Device. PLoS ONE, 2012, 7, e33122.	1.1	8

#	Article	IF	CITATIONS
91	Haploidentical Mismatched Allogeneic Versus Autologous Hematopoietic STEM CELL Transplantation in Adult Patients with ACUTE Myeloid Leukemia (AML) in First Complete Remission (CR1): A Pair-Matched Analysis From the Acute Leukemia Working Party of EBMT Blood, 2012, 120, 3093-3093.	0.6	0
92	Impact of Myeloablative and Reduced Intensity Conditioning On Outcomes After Unrelated Cord Blood Transplantation for Adults with Acute Lymphoblastic Leukemia Blood, 2012, 120, 3117-3117.	0.6	0
93	Unmanipulated, G-CSF-Primed Bone Marrow Transplantation From Haploidentical Donor for Patients with High-Risk Acute Myeloid Leukemia Blood, 2012, 120, 3122-3122.	0.6	0
94	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. Blood, 2012, 120, 1975-1975.	0.6	5
95	Validation of the Cibmtr Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood, 2012, 120, 2005-2005.	0.6	0
96	Alkylator-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) in Lymphoma: A Registry Study Comparing Thiotepa-, Busulfan-, Melphalan- and Treosulfan-Containing Regimens On Behalf of the EBMT Lymphoma Working Party. Blood, 2012, 120, 2033-2033.	0.6	0
97	Unmanipulated Graft Transplantation From Family Haploidentical Donors: A Survey On 183 Adult Patients with Acute Leukemias On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2012, 120, 1987-1987.	0.6	0
98	Long Telomere Length of White Blood Cells Following Umbilical Cord Blood Transplant (UCBT): Is Hematopoiesis Younger in UCBT Recipients Compared to Healthy Age-Matched Controls?. Blood, 2012, 120, 4094-4094.	0.6	0
99	Are Outcomes After Myeloablative Conditioning Regimen in Double Cord Blood Transplantation (UCBT) Better Than Single UCBT for Adults with Acute Leukemia in Remission? Blood, 2012, 120, 3083-3083.	0.6	0
100	Comparative Efficacy Analysis of Busulfan Dose Intensity Between Two Reduced Intensity Conditioning Regimens (FB2 vs. FB4) for Allogeneic HCT for AML in First Complete Remission: A Report From the EBMT Acute Leukemia Working Party. Blood, 2012, 120, 4153-4153.	0.6	0
101	Algorithm for donor selection in 2011. Current Opinion in Hematology, 2011, 18, 401-407.	1.2	10
102	Stem Cell Transplantation Can Provide Durable Disease Control in Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC): A Retrospective Study From the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2011, 118, 3077-3077.	0.6	1
103	Homecare-based motor rehabilitation in musculoskeletal chronic graft versus host disease. Indian Journal of Palliative Care, 2011, 17, 159.	1.0	6
104	The Presence of An Internal Tandem Duplicate of FIT3 Receptor (ITD) Is An Unfavorable Prognostic Factor on the Outcome of Adult Patients with Acute Myeloid Leukemia (AML) Autografted in First Remission (CR1) Only in the Absence of An NPM1 Mutation,. Blood, 2011, 118, 4139-4139.	0.6	0
105	tk;4ls There an Impact of HLA Mismatch Direction on Outcomes After Umbilical Cord Blood Transplantantion?. Blood, 2011, 118, 835-835.	0.6	0
106	Intravenous Busulfan (IV Bu)-Based Conditioning Regimen Before Allogeneic Stem Cell Transplantation (allo-SCT) for Adults with Acute Lymphoid Leukemia (ALL): A Aurvey From the Acute Leukemia Working Party of EBMT. Blood, 2011, 118, 3005-3005.	0.6	1
107	Unrelated Cord Blood Transplantation Using Myeloablative Conditioning Regimen for Adults with Acute Myeloid Leukemia in First Complete Remission. A Survey by EUROCORD and the Acute Leukemia Working Party of the EBMT. Blood, 2011, 118, 836-836.	0.6	0
108	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood, 2010, 116, 2295-2303.	0.6	126

#	Article	IF	CITATIONS
109	Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. American Journal of Hematology, 2010, 85, 380-383.	2.0	12
110	Platelet gel for treatment of mucocutaneous lesions related to graftâ€versusâ€host disease after allogeneic hematopoietic stem cell transplant. Transfusion, 2010, 50, 501-506.	0.8	23
111	Standard―versus highâ€dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization. Transfusion, 2010, 50, 2432-2446.	0.8	14
112	Thrombophilic screening in patients with paroxysmal nocturnal haemoglobinuria: a pilot study. British Journal of Haematology, 2010, 150, 492-494.	1.2	11
113	Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid Tamibarotene. British Journal of Haematology, 2010, 151, 99-101.	1.2	12
114	Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and S $ ilde{A}$ ©zary Syndrome: A Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2010, 28, 4492-4499.	0.8	191
115	High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2010, 28, 2227-2232.	0.8	131
116	Cord blood transplantation in adults with acute myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2010, 23, 197-206.	0.7	4
117	Quality assessment of cord blood units selected for unrelated transplantation: A Transplant Center perspective. Transfusion and Apheresis Science, 2010, 42, 289-297.	0.5	19
118	Pre-transplant manipulation processing of umbilical cord blood units: Efficacy of Rubinstein's thawing technique used in 40 transplantation procedures. Transfusion and Apheresis Science, 2010, 43, 173-178.	0.5	4
119	Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncology, The, 2010, 11, 653-660.	5.1	532
120	Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study. Blood, 2010, 116, 910-910.	0.6	8
121	MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option. Blood, 2010, 116, 2702-2702.	0.6	O
122	Incidence and Risk Factors of Chronic Graft-Versus-Host Disease After Unrelated Cord Blood Transplant In Children and Adults. A Retrospective Study on Behalf of EUROCORD and Late-Effect Working Party of EBMT. Blood, 2010, 116, 219-219.	0.6	0
123	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Cord Blood Transplantation (CBT). Retrospective Analysis on Behalf of Eurocord and the EBMT Autoimmune Diseases Working Party Blood, 2010, 116, 3460-3460.	0.6	0
124	Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders. Journal of Medical Virology, 2009, 81, 1668-1673.	2.5	40
125	Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion. Bone Marrow Transplantation, 2009, 43, 347-348.	1.3	9
126	Fibrin glue for refractory hemorrhagic cystitis after unrelated marrow, cord blood, and haploidentical hematopoietic stem cell transplantation. Transfusion, 2009, 49, 170-175.	0.8	24

#	Article	IF	CITATIONS
127	A fatal case of invasive fungal sinusitis by Scopulariopsis acremonium in a bone marrow transplant recipient. International Journal of Infectious Diseases, 2009, 13, e488-e492.	1.5	17
128	Monitoring of minimal residual disease in acute myeloid leukemia. Current Opinion in Oncology, 2009, 21, 582-588.	1.1	24
129	Non T-Depleted Bone Marrow Transplantation From Haploidentical Related Donor in Hematological Malignancies Blood, 2009, 114, 2291-2291.	0.6	2
130	"An Intention-to-Treat Analysis of Rome Transplant Network Policy for Alternative Donor Search in Patients Lacking a HLA Matched Related donorâ€. Blood, 2009, 114, 1195-1195.	0.6	0
131	Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia. Journal of Clinical Oncology, 2008, 26, 4944-4951.	0.8	165
132	Influence of Myeloablative Conditioning Regimens on Outcomes after Single Unrelated Cord Blood Transplantation for Adults with Leukemia: An Analysis on Behalf of Eurocord-EBMT-Netcord. Blood, 2008, 112, 155-155.	0.6	4
133	Standard Versus High Dose Lenograstim in Adults with Hematological Malignancies for Peripheral Blood Progenitor Cell Mobilization: Results of a Retrospective Study on Behalf of Rome Transplant Network Blood, 2008, 112, 2302-2302.	0.6	0
134	Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2007, 39, 461-469.	1.3	55
135	HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. Leukemia, 2007, 21, 129-135.	3.3	50
136	Does the volume reduction manipulation before cryopreservation influence cord blood cell recovery pretransplant?. Transfusion Medicine, 2007, 17, 208-209.	0.5	3
137	Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up. Haematologica, 2007, 92, 1051-1058.	1.7	11
138	Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood, 2006, 107, 4177-4181.	0.6	158
139	The Therapeutic Use of Cord Blood. Cell Preservation Technology, 2006, 4, 161-168.	0.8	4
140	Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica, 2006, 91, 223-30.	1.7	83
141	Histone Deacetylase Inhibitor Valproic Acid Enhances the Cytokine-Induced Expansion of Human Hematopoietic Stem Cells. Cancer Research, 2005, 65, 1505-1513.	0.4	147
142	Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. New England Journal of Medicine, 2004, 351, 2276-2285.	13.9	1,058
143	Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Journal of Clinical Oncology, 2004, 22, 416-423.	0.8	173
144	Pre-transplant prognostic factors for patients with high-risk leukemia undergoing an unrelated cord blood transplantation. Bone Marrow Transplantation, 2004, 33, 1097-1105.	1.3	33

#	Article	IF	Citations
145	ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature. Bone Marrow Transplantation, 2004, 34, 321-329.	1.3	35
146	Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice. Experimental Hematology, 2004, 32, 397-407.	0.2	384
147	Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. Annals of Hematology, 2003, 82, 189-192.	0.8	37
148	Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplantation, 2003, 31, 295-300.	1.3	65
149	Impact of marrow unrelated donor search duration on outcome of children with acute lymphoblastic leukemia in second remission. Bone Marrow Transplantation, 2003, 32, 325-331.	1.3	26
150	Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia, 2003, 17, 1930-1933.	3.3	41
151	Stem cell transplantation for chronic myeloid leukemia in children. Blood, 2003, 102, 1224-1231.	0.6	99
152	Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood, 2003, 102, 3043-3051.	0.6	52
153	Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood, 2003, 102, 4290-4297.	0.6	160
154	Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey. Journal of Clinical Oncology, 2002, 20, 4324-4330.	0.8	65
155	Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood, 2002, 100, 397-405.	0.6	186
156	Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2002, 20, 4655-4664.	0.8	136
157	A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood â€ ⁻ high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group. British Journal of Haematology, 2002, 118, 741-747.	1.2	18
158	Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Lancet, The, 2001, 357, 43-44.	6.3	72
159	CD34+ cell mobilization for allogeneic progenitor cell transplantation: efficacy of a short course of G-CSF. Transfusion, 2001, 41, 190-195.	0.8	22
160	Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood, 2001, 97, 2962-2971.	0.6	720
161	High levels of antiphospholipid antibodies are associated with cytomegalovirus infection in unrelated bone marrow and cord blood allogeneic stem cell transplantation. British Journal of Haematology, 2000, 108, 126-131.	1.2	34
162	Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. Leukemia, 2000, 14, 2052-2058.	3.3	8

#	Article	IF	CITATIONS
163	Listeriosis in Recipients of Allogeneic Bone Marrow Transplants from Unrelated Donors. European Journal of Clinical Microbiology and Infectious Diseases, 2000, 19, 711-714.	1.3	11
164	Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood, 2000, 95, 1931-1934.	0.6	243
165	Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet, The, 2000, 355, 1393-1398.	6.3	99
166	A prospective molecular study of chimaerism in patients with haematological malignancies receiving unrelated cord blood or bone marrow transplants: detection of mixed chimaerism predicts graft failure with or without early autologous reconstitution in cor. British Journal of Haematology, 1999, 104, 770-777.	1.2	12
167	Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. British Journal of Haematology, 1999, 106, 133-141.	1.2	21
168	Umbilical cord blood transplant from unrelated HLA-mismatched donors in children with high risk leukemia. Bone Marrow Transplantation, 1999, 23, 549-554.	1.3	16
169	Pregnancy and secondary cancer after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1999, 23, 752-752.	1.3	3
170	Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Bone Marrow Transplantation, 1999, 24, 47-51.	1.3	84
171	Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood, 1999, 93, 3662-71.	0.6	230
172	Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet, The, 1998, 352, 1087-1092.	6.3	609
173	Fractionated total body irradiation in allogeneic bone marrow transplantation in leukemia patients: analysis of prognostic factors and results in 136 patients. Radiotherapy and Oncology, 1998, 48, 267-276.	0.3	5
174	Gastrointestinal Emergencies in Patients with Acute Intestinal Graft-Versus-Host Disease. Leukemia and Lymphoma, 1998, 29, 129-137.	0.6	32
175	Management of Advanced Acute Lymphoblastic Leukemia in Children and Adults: Results of the ALL R-87 Protocol. Leukemia and Lymphoma, 1998, 32, 89-95.	0.6	6
176	CLINICAL AND METABOLIC EFFECTS OF DIFFERENT PARENTERAL NUTRITION REGIMENS IN PATIENTS UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION1. Transplantation, 1998, 66, 610-616.	0.5	56
177	Clinical use of allogeneic hematopoietic stem cells from sources other than bone marrow. Haematologica, 1998, 83, 159-82.	1.7	13
178	Outcome of Cord-Blood Transplantation from Related and Unrelated Donors. New England Journal of Medicine, 1997, 337, 373-381.	13.9	1,255
179	Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation. Bone Marrow Transplantation, 1997, 19, 703-707.	1.3	30
180	Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 1997, 20, 553-560.	1.3	134

#	Article	IF	Citations
181	Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL Râ€87 protocol. British Journal of Haematology, 1997, 97, 896-903.	1.2	32
182	ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. British Journal of Haematology, 1997, 99, 671-677.	1.2	30
183	Allogeneic bone marrow transplantation versus chemotherapy in high-risk childhood acute lymphoblastic leukaemia in first remission. British Journal of Haematology, 1997, 96, 387-394.	1.2	37
184	Transcription of latent and replicative Epstein-Barr-virus genes in bone-marrow and peripheral-blood mononuclear cells of healthy donors., 1997, 70, 524-529.		16
185	A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome. Haematologica, 1997, 82, 19-22.	1.7	2
186	A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. British Journal of Haematology, 1996, 93, 637-646.	1.2	133
187	Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. British Journal of Haematology, 1996, 95, 494-500.	1.2	17
188	Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]. Blood, 1995, 86, 2041-2050.	0.6	1,911
189	Myelodysplastic syndromes in childhood: description of seven cases. Annals of Hematology, 1994, 68, 241-245.	0.8	6
190	5 The interferons in haematological malignancies. Best Practice and Research: Clinical Haematology, 1994, 7, 91-113.	1.1	6
191	Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP*experience. British Journal of Haematology, 1994, 86, 55-61.	1.2	45
192	The Surgical Choice in Neutropenic Patients with Hematological Disorders and Acute Abdominal Complications. Leukemia and Lymphoma, 1993, 9, 237-241.	0.6	52
193	Splenic Irradiation before Bone Marrow Transplantation for Chronic Myeloid Leukemia: Update of a Prospective Randomized Study. Leukemia and Lymphoma, 1993, 11, 227-231.	0.6	4
194	What Does One do for the CML Patient in Relapse After Allogeneic Bone Marrow Transplantation?. Leukemia and Lymphoma, 1993, 11, 213-219.	0.6	2
195	Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood, 1993, 82, 3211-3219.	0.6	99
196	Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood, 1993, 82, 3211-3219.	0.6	22
197	Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. Blood, 1993, 82, 3211-9.	0.6	8
198	Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplantation, 1993, 12, 509-16.	1.3	92

#	Article	IF	CITATION
199	Onychomycosis As a Possible Origin of Disseminated Fusarium solani Infection in a Patient with Severe Aplastic Anemia. Clinical Infectious Diseases, 1992, 14, 1167-1167.	2.9	88
200	Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet, The, 1992, 340, 1437-1438.	6.3	214
201	No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia: results of a prospective randomized study. Bone Marrow Transplantation, 1992, 10, 147-52.	1.3	12
202	Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia Journal of Clinical Oncology, 1991, 9, 1210-1214.	0.8	152
203	Cytogenetic follow-up after allogeneic bone-marrow transplantation for Ph1-positive chronic myelogenous leukemia. Bone Marrow Transplantation, 1990, 5, 119-27.	1.3	13
204	Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1990, 5, 309-15.	1.3	26
205	Italian survey on allogeneic BMT for chronic myeloid leukaemia. Bone Marrow Transplantation, 1989, 4 Suppl 4, 90-1.	1.3	0
206	Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. British Journal of Haematology, 1988, 69, 239-245.	1.2	183
207	Hemolysis in Rh-negative female recipient after Rh-incompatible bone marrow transplantation for chronic myeloid leukemia. Haematologica, 1986, 71, 46-9.	1.7	14
208	Bone Marrow Transplantation in Severe Aplastic Anaemia: a Survey of the European Group for Bone Marrow Transplantation (E.G.B.M.T.). British Journal of Haematology, 1981, 49, 165-173.	1.2	69